MBC

Milwaukee Boot Company Debuts First-Ever Women's Line, Names New Local Brand Ambassadors

Retrieved on: 
火曜日, 11月 7, 2023
Female, Woman, Sport, System, History, Femininity, Partnership, Love, DTC, MBC, Morality, Hearing, Shoemaking

MILWAUKEE, Nov. 7, 2023 /PRNewswire/ -- Premium footwear and accessories brand Milwaukee Boot Company (MBC) is thrilled to announce the launch of their first women's line, joining MBC's handcrafted, quality men's product selection that embraces the spirit of Midwestern work ethic and the history of Milwaukee as a leader in leather manufacturing.

Key Points: 
  • We saw the opportunity to fill this gap, and are thrilled to add dedicated women's products to Milwaukee Boot Company's lineup.
  • Our team worked to infuse a touch of femininity into the robust structures, ensuring that every product exudes both strength and grace," says Zaid Malack, CEO of Milwaukee Boot Company and Moral Code.
  • Helping to usher in this exciting new development for the brand are its new brand ambassadors, husband-and-wife duo Zora Stephenson and Kevin Blake.
  • Below are Milwaukee Boot Company's new women's footwear and accessory styles:

MasterBrand to Present at Baird’s Global Industrial Conference

Retrieved on: 
木曜日, 10月 26, 2023
Manufacturing, Interior Design, Other Manufacturing, Residential Building & Real Estate, Construction & Property, Conference, Central Time, MBC, NYSE, Webcast, Cryptocurrency

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced that Dave Banyard, President and Chief Executive Officer, and Andi Simon, Executive Vice President and Chief Financial Officer, will present at Baird’s Global Industrial Conference in Chicago on Thursday, November 9, 2023, at 1:10pm Central Time.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced that Dave Banyard, President and Chief Executive Officer, and Andi Simon, Executive Vice President and Chief Financial Officer, will present at Baird’s Global Industrial Conference in Chicago on Thursday, November 9, 2023, at 1:10pm Central Time.
  • The presentation will be webcast live on the Investors section of the Company’s website at www.masterbrand.com , and a replay of the webcast will be archived on the website for a limited time.
  • The Company will also host investor meetings throughout the conference.

Behavioral Health Study Uncovers Remarkable Results: Measurement-Based Care with Owl Reduces Behavioral Health Adverse Events, Slashes Costs for Colorado Medicaid Plan

Retrieved on: 
水曜日, 10月 25, 2023
Aurora, Patient, Public sector, AURORA, HEDIS, Aurora Mental Health & Recovery, Owl, MBC, Health, Partnership, Medicaid, Nursing, Hospital, Health insurance, Pharmaceutical industry, Management

AURORA, Colo., Oct. 25, 2023 /PRNewswire/ -- Owl, a behavioral health technology company, today announced the results of a measurement-based care (MBC) impact study in collaboration with Colorado Access, the largest public sector health plan in Colorado, and Aurora Mental Health & Recovery, a certified community behavioral health clinic.

Key Points: 
  • AURORA, Colo., Oct. 25, 2023 /PRNewswire/ -- Owl , a behavioral health technology company, today announced the results of a measurement-based care (MBC) impact study in collaboration with Colorado Access , the largest public sector health plan in Colorado, and Aurora Mental Health & Recovery , a certified community behavioral health clinic.
  • Behavioral health study shows the power of MBC in improving patient care and outcomes while delivering cost savings.
  • "The results from this measurement-based care impact study are astounding," said Lindsay Cowee, senior director of behavioral health network performance at Colorado Access.
  • Aurora Mental Health & Recovery is a certified community behavioral health clinic on a mission to elevate the standards of behavioral health care.

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

Retrieved on: 
木曜日, 10月 19, 2023
European Organisation for Research and Treatment of Cancer, Patient, Research, Arm, Metastasis, Plasma, Clinical trial, European Commission, III, SERD, Treatment, SUCCESS, EORTC, Menarini, HIV disease progression rates, German, DNA, Civil service commission, MBC, MRD, Breast cancer, Breast International Group, Woman, Neoplasm, Death, Treat, BIG, Pharmaceutical industry, Medical imaging, Cancer

A molecular residual disease (MRD) test for the detection of circulating tumour DNA (ctDNA) will also be used.

Key Points: 
  • A molecular residual disease (MRD) test for the detection of circulating tumour DNA (ctDNA) will also be used.
  • The study was submitted under the new Clinical Trial Regulation, and it is expected to start the activation process in the fourth quarter of 2023.
  • "We are excited to offer to our high-risk, ctDNA positive, ER+/HER2- early-stage breast cancer patients the possibility to participate in the Treat ctDNA trial.
  • This intergroup trial, managed by the EORTC Breast Cancer Group, will be jointly conducted with several national and international cancer clinical research groups, including the German SUCCESS group under the umbrella of BIG (Breast International Group).

LiveOne (LVO) Subsidiary LiveXLive Partners With METAvivor to Fight Metastatic Breast Cancer, Live Streaming #LightUpMBC Live on October 13, 2023 to 220 Countries

Retrieved on: 
月曜日, 10月 9, 2023
Wells Fargo Center, LiveOne, LVO, Caesars Superdome, Lighting, City Hall, Cork, U.S. Bank Stadium station, BC Place, Miami-Dade Arena, Disease, Lincoln Financial Field, Waiting staff, MBC, Support, U.S. Bank Stadium, Rock and Roll Hall of Fame, Citizens Bank Park, Research, Birth control, Entertainment

LOS ANGELES, CA, Oct. 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- LiveOne (Nasdaq: LVO), an award-winning, creator-first music, entertainment, and technology platform, is excited to announce its collaboration with METAvivor Research and Support for the fifth annual #LightUpMBC Live event. On October 13, 2023, National Metastatic Breast Cancer Awareness Day, LiveOne will livestream the event, lighting over 275 landmarks across all 50 U.S. states, D.C., Puerto Rico, Canada, Australia, England, Ireland and more in the distinctive MBC awareness colors of green, teal, and pink.

Key Points: 
  • This global event, fueled by hundreds of #LightUpMBC ambassadors, seeks to raise vital awareness and funds for metastatic breast cancer research.
  • #LightUpMBC Live will feature compelling MBC patient stories and musical performances to drive funds for MBC research.
  • Jamil Rivers, METAvivor President, urges donations for crucial stage IV MBC research, stating, "It's the singular path to offering extensions to lives confronting this terminal illness."
  • For more information, to donate and view a list of participating landmarks, visit:

Gilead and Kite Oncology Present Important New Data Across Multiple Difficult-to-Treat Cancers at ESMO Congress 2023

Retrieved on: 
月曜日, 10月 16, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Congress, Neoplasm, Multimedia, Cancer, Senior, Doctor of Philosophy, HNSCC, MD, ESMO, B-cell lymphoma, Carcinoma, CAR, Head, TNBC, European Society for Medical Oncology, MBC, Patient, Dana–Farber Cancer Institute, Pharmaceutical industry, Sacituzumab govitecan, Axicabtagene ciloleucel

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present new data, including three oral presentations, at the European Society for Medical Oncology (ESMO) Congress 2023.
  • Kite will also present analyses supporting the use of Yescarta® (axicabtagene ciloleucel) in relapsed/refractory large B-Cell lymphoma (LBCL).
  • View the full release here: https://www.businesswire.com/news/home/20231015111917/en/
    “Our data at ESMO 2023 reflect a broad clinical development program in difficult-to-treat cancers,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology.
  • “We believe our data will help further clinicians’ understanding of when to use Yescarta in these patients and reinforce confidence in CAR T-cell therapies overall.”

MasterBrand to Announce Third Quarter 2023 Results on November 7

Retrieved on: 
火曜日, 10月 10, 2023
Manufacturing, Interior Design, Other Manufacturing, Residential Building & Real Estate, Construction & Property, NYSE, Webcast, MBC, Broadcasting

MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will release its third quarter 2023 financial results after the market close on Tuesday, November 7, 2023.

Key Points: 
  • MasterBrand, Inc. (NYSE: MBC, the “Company,” or “MasterBrand”), the largest residential cabinet manufacturer in North America, today announced it will release its third quarter 2023 financial results after the market close on Tuesday, November 7, 2023.
  • ET the same day to discuss the financial results and business outlook.
  • The live audio webcast can be accessed on the “Investors” section of the MasterBrand website at www.masterbrand.com .
  • A telephone replay will be available approximately one hour following completion of the call through November 21, 2023.

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Retrieved on: 
火曜日, 10月 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, NYSE, Abstract, Breast cancer, Brentuximab vedotin, INT, Trastuzumab, RCC, Survival, Endometrial cancer, PEM, NRG, ESMO, Merck & Co., Webcast, Belzutifan, European Society for Medical Oncology, ADC, Research, TUC, KRAS, Lung cancer, RAS, AstraZeneca, EC, Adenocarcinoma, Head, TNBC, MRK, Pembrolizumab, Everolimus, CRC, Cancer, Olaparib, EFS, Quality of life (healthcare), SWOG, Congress, LBA32, LBA21, PBO, Chemoradiotherapy, CP, Safety, MBC, Patient, Pharmaceutical industry, Birth control, Medical imaging, Animal feed, Vaccine, Tras, Merck, NSCLC, Eisai

The event will take place virtually and will be accessible via webcast.

Key Points: 
  • The event will take place virtually and will be accessible via webcast.
  • Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC.
  • Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801.
  • mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response.

166 Cities Around The World Unite To Shine A Light On The Only Terminal Breast Cancer

Retrieved on: 
水曜日, 10月 11, 2023
Hope, LiveOne, Memorial Bridge, Breast cancer, Personality, Breast, BC Place, Lite FM, Memory, Disease, Cancer, Memory Bridge, Patient, SA1 Swansea Waterfront, Spirituality, Metastasis, Waiting staff, MBC, Support, Research, PECO, Radio, Birth control

ANNAPOLIS, Md., Oct. 11, 2023 /PRNewswire-PRWeb/ -- METAvivor Research and Support announces the launch of the fifth annual global landmark campaign, #LightUpMBC, to shine a light on the importance of awareness and funding for metastatic breast cancer (MBC) research. Every year, more than 685,000 people worldwide die from MBC, also known as Stage 4 or advanced breast cancer, for which there is no cure. MBC is when the cancer spreads beyond the breast to other parts of the body.

Key Points: 
  • Every year, more than 685,000 people worldwide die from MBC, also known as Stage 4 or advanced breast cancer, for which there is no cure.
  • MBC is when the cancer spreads beyond the breast to other parts of the body.
  • While pink has long been synonymous with early stage breast cancer awareness, pink alone does not resonate with the advanced stage MBC community.
  • "Metastatic breast cancer is the only terminal breast cancer.

Hexagon expands TerraStar-X precise positioning GNSS correction service to South Korea

Retrieved on: 
水曜日, 10月 4, 2023
Autonomy, Munhwa Broadcasting Corporation, Enterprise, Smartphone, Multimedia, Korea Correctional Service, PPP, MBC, ADAS, RTK, Satellite navigation device, Surveying, Hexagon

CALGARY, Canada, Oct. 4, 2023 /PRNewswire-PRWeb/ -- Hexagon's Autonomy & Positioning division and Munhwa Broadcasting Corporation (MBC) proudly announce their agreement to bring precise positioning to South Korea through the TerraStar-X Enterprise Correction Service. The hardware-agnostic correction service provides instant convergence and lane-level accuracy in automotive, mobile and autonomous applications.

Key Points: 
  • CALGARY, Canada, Oct. 4, 2023 /PRNewswire-PRWeb/ -- Hexagon's Autonomy & Positioning division and Munhwa Broadcasting Corporation (MBC) proudly announce their agreement to bring precise positioning to South Korea through the TerraStar-X Enterprise Correction Service.
  • The hardware-agnostic correction service provides instant convergence and lane-level accuracy in automotive, mobile and autonomous applications.
  • As a leader in real-time kinematic (RTK) positioning across South Korea, MBC's atmospheric data enhances the redundancy of Hexagon's fast converging and reliable precise point positioning (PPP) network across the country.
  • Jessica Fielding, Hexagon's Autonomy & Positioning division, +1.403.919.3388, [email protected] , https://novatel.com/terrastar-x
    Youngji Bae, Hexagon's Autonomy & Positioning division, +82.10.3481.0091, [email protected] , https://novatel.com/terrastar-x
    View original content to download multimedia: https://www.prweb.com/releases/hexagon-expands-terrastar-x-precise-posit...